CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Charu Aggarwal, MD, MPH, FASCO on X: The landscape of #EarlyStage

Ahmed Magdy Rabea on LinkedIn: Thank you IASLC for the amazing

Cancers, Free Full-Text

Perioperative Nivolumab Improves EFS in NSCLC - Cancer Therapy Advisor

主席专场四大临床研究数据披露，改写多个癌种治疗新格局｜ESMO重磅速递

News from ESMO - Lung Cancer Research Foundation

Pre- and Post-Surgical Immunotherapy Improves Survival Rates for

LUNG CANCER

Dipesh Uprety MD FACP on X: CheckMate-77T #ESMO23 @ESMO